Unity Biotechnology Inc (UBX)

$0.94 -0.03 (-3.09%)
Market Cap 16.36M
Revenue (ttm) 0.00
Net Income (ttm) -25.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 128,300
Avg Vol 176,310
Day's Range N/A - N/A
Shares Out 16.87M
Stochastic %K 40%
Beta 1.30
Analysts Strong Sell
Price Target $5.50

Latest News on UBX

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

Mar 24, 2025, 11:26 AM EDT - 4 weeks ago

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

Mar 24, 2025, 7:01 AM EDT - 4 weeks ago

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

Mar 23, 2025, 4:00 PM EDT - 4 weeks ago

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 7, 2025, 4:30 PM EST - 6 weeks ago

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

UNITY Biotechnology Reports Granting of New Employment Inducement Award

Jan 7, 2025, 4:10 PM EST - 3 months ago

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

Jan 6, 2025, 8:00 AM EST - 3 months ago

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:30 PM EST - 6 months ago

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

Aug 6, 2024, 4:30 PM EDT - 9 months ago

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

Jul 22, 2024, 8:00 AM EDT - 9 months ago

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 5:00 PM EDT - 1 year ago

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

Apr 25, 2024, 8:00 AM EDT - 1 year ago

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Apr 23, 2024, 8:00 AM EDT - 1 year ago

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Apr 15, 2024, 7:00 AM EDT - 1 year ago

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Feb 6, 2024, 8:00 AM EST - 1 year ago

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Dec 12, 2023, 8:00 AM EST - 1 year ago

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

Nov 13, 2023, 4:05 PM EST - 1 year ago

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

Nov 10, 2023, 8:00 AM EST - 1 year ago

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Sep 27, 2023, 7:00 AM EDT - 1 year ago

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

Aug 8, 2023, 4:05 PM EDT - 1 year ago

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

Jun 21, 2023, 7:00 AM EDT - 1 year ago

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

Apr 24, 2023, 7:00 AM EDT - 2 years ago

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

Apr 23, 2023, 6:00 PM EDT - 2 years ago

UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Mar 27, 2023, 7:30 AM EDT - 2 years ago

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Mar 15, 2023, 4:05 PM EDT - 2 years ago

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

Feb 28, 2023, 4:05 PM EST - 2 years ago

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

Nov 8, 2022, 4:10 PM EST - 2 years ago

UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

Nov 1, 2022, 7:00 AM EDT - 2 years ago

UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results

Oct 24, 2022, 8:15 AM EDT - 2 years ago

Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results

UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today

Oct 19, 2022, 8:30 AM EDT - 2 years ago

UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today

UNITY Biotechnology's Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye

Oct 11, 2022, 8:00 AM EDT - 2 years ago

UNITY Biotechnology's Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye

UNITY Biotechnology to Participate in Upcoming Investor Conferences

Aug 31, 2022, 8:00 AM EDT - 2 years ago

UNITY Biotechnology to Participate in Upcoming Investor Conferences

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

Aug 17, 2022, 11:04 PM EDT - 2 years ago

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

Aug 16, 2022, 4:01 PM EDT - 2 years ago

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

Aug 12, 2022, 7:05 AM EDT - 2 years ago

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

Aug 12, 2022, 7:00 AM EDT - 2 years ago

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

Aug 11, 2022, 5:45 PM EDT - 2 years ago

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

Jul 12, 2022, 4:00 PM EDT - 3 years ago

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

May 26, 2022, 8:00 AM EDT - 3 years ago

UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

May 10, 2022, 4:00 PM EDT - 3 years ago

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

May 5, 2022, 8:00 AM EDT - 3 years ago

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Apr 12, 2022, 8:00 AM EDT - 3 years ago

UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

Mar 15, 2022, 8:00 AM EDT - 3 years ago

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

Mar 1, 2022, 8:00 AM EST - 3 years ago

UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Feb 14, 2022, 8:00 AM EST - 3 years ago

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

Feb 3, 2022, 4:01 PM EST - 3 years ago

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

Dec 20, 2021, 8:00 AM EST - 3 years ago

UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?

Nov 10, 2021, 12:35 PM EST - 3 years ago

Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?

UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

Nov 10, 2021, 8:00 AM EST - 3 years ago

UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

Nov 9, 2021, 7:00 AM EST - 3 years ago

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

Nov 3, 2021, 8:00 AM EDT - 3 years ago

UNITY Biotechnology Reports Granting of New Employment Inducement Awards